ArticleEJNMMI research2024
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.
Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01842165 (The LuMEn Study), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours.
Who cites it
8 citing papers in PubMed.
- Patient Survival and Its Relation to Tumor Absorbed Dose in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Semiquantitative SSTR PET metrics show molecular-morphologic discordance after 177Lu-DOTATATE in gastroenteropancreatic neuroendocrine neoplasms: an exploratory paired target-lesion analysis.Annals of nuclear medicine · 2026Article
- Long-term toxicity of tandem radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2026Article
- FAP-Targeted Radionuclide Therapy: Mechanisms, Clinical Applications, and Combination Strategies.Biomedicines · 2026Review
- Validation of Simplified Renal Dosimetry Protocols forMolecular imaging and radionuclide therapy · 2026Article
- Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Review
- Multicycle Dosimetric Behavior and Dose-Effect Relationships in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPeptide receptor radionuclide therapy (PRRT) with [
resultsThere is an important variability in absorbed doses and activity concentrations among patients, particularly in tumours (CoV: ~50%). Tumour absorbed doses and activity concentrations decreased over treatment cycles in pancreatic NETs, although at a limited rate (~-13%/cycle). An opposite trend was observed for the kidneys ( ~ + 8%/cycle). Effective half-lives remained relatively constant across cycles for both organs-at-risk and tumours. The primary NET type significantly influenced effective half-lives in tumours, shorter in pancreatic NETs than intestinal NETs (77 h vs. 107 h, p < 0.0001). No significant effect of the grade was observed on either of the variables investigated.
conclusionsOur study revealed considerable variations in tumour absorbed doses among patients with NETs treated with a standardized protocol. These findings confirm the need for personalized dosimetry approaches in PRRT, considering patient and tumour characteristics.
trial registrationEudraCT Number: 2012-003666-41. CLINICALTRIALS: gov identifier: NCT01842165. Registered 25 April 2013, https://clinicaltrials.gov/ct2/show/NCT01842165 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.